{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:11:36Z","timestamp":1792980696660,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00520-020-05702-8","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T21:03:42Z","timestamp":1598475822000},"page":"2029-2035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Seren","family":"Aksun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Taban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktay Halit","family":"Aktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan Metin","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Akka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"5702_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116\u2013129. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.035","journal-title":"Eur J Cancer"},{"key":"5702_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765\u2013772","journal-title":"Int Immunol"},{"key":"5702_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734\u20131736","journal-title":"Science"},{"key":"5702_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S et al (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11:39. https:\/\/doi.org\/10.1186\/s13045-018-0582-8","journal-title":"J Hematol Oncol"},{"key":"5702_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/cpt.985","volume":"103","author":"JS McCune","year":"2018","unstructured":"McCune JS (2018) Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther 103:540\u2013544. https:\/\/doi.org\/10.1002\/cpt.985","journal-title":"Clin Pharmacol Ther"},{"key":"5702_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-018-0684-3","volume":"11","author":"Z Li","year":"2018","unstructured":"Li Z, Song W, Rubinstein M, Liu D (2018) Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol 11:142. https:\/\/doi.org\/10.1186\/s13045-018-0684-3","journal-title":"J Hematol Oncol"},{"key":"5702_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T et al (2016) Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"5702_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"5702_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"5702_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"key":"5702_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"5702_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2014","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC et al (2014) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"5702_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJMp1510079","volume":"373","author":"A Ribas","year":"2015","unstructured":"Ribas A (2015) Releasing the brakes on cancer immunotherapy. N Engl J Med 373:1490\u20131492. https:\/\/doi.org\/10.1056\/NEJMp1510079","journal-title":"N Engl J Med"},{"key":"5702_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Wolchok JD et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391. https:\/\/doi.org\/10.1093\/annonc\/mdv383","journal-title":"Ann Oncol"},{"key":"5702_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"5702_CR16","doi-asserted-by":"publisher","first-page":"e1774","DOI":"10.7759\/cureus.1774","volume":"9","author":"D Simmons","year":"2017","unstructured":"Simmons D, Lang E (2017) The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors. Cureus 9:e1774. https:\/\/doi.org\/10.7759\/cureus.1774","journal-title":"Cureus"},{"key":"5702_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-26387-8","volume-title":"Oncologic emergency medicine: principles and practice","author":"KH Todd","year":"2016","unstructured":"Todd KH, Thomas CR Jr (2016) Oncologic emergency medicine: principles and practice. Springer, Berlin"},{"key":"5702_CR18","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1002\/cam4.1728","volume":"7","author":"TH Wong","year":"2018","unstructured":"Wong TH, Lau ZY, Ong WS, Tan KB, Wong YJ et al (2018) Cancer patients as frequent attenders in emergency departments: a national cohort study. Cancer Med 7:4434\u20134446. https:\/\/doi.org\/10.1002\/cam4.1728","journal-title":"Cancer Med"},{"key":"5702_CR19","doi-asserted-by":"publisher","first-page":"e172450","DOI":"10.1001\/jamaoncol.2017.2450","volume":"3","author":"DR Rivera","year":"2017","unstructured":"Rivera DR, Gallicchio L, Brown J, Liu B, Kyriacou DN et al (2017) Trends in adult cancer\u2013related emergency department utilization: an analysis of data from the nationwide emergency department sample. JAMA Oncol 3:e172450. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2450","journal-title":"JAMA Oncol"},{"key":"5702_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5847\/wjem.j.issn.1920-8642.2014.02.001","volume":"5","author":"M Sadik","year":"2014","unstructured":"Sadik M, Ozlem K, Huseyin M, AliAyberk B, Ahmet S et al (2014) Attributes of cancer patients admitted to the emergency department in one year. World J Emerg Med 5:85\u201390. https:\/\/doi.org\/10.5847\/wjem.j.issn.1920-8642.2014.02.001","journal-title":"World J Emerg Med"},{"key":"5702_CR21","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2010.34.2816","volume":"29","author":"DK Mayer","year":"2011","unstructured":"Mayer DK, Travers D, Wyss A, Leak A, Waller A (2011) Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol Off J Am Soc Clin Oncol 29:2683\u20132688. https:\/\/doi.org\/10.1200\/JCO.2010.34.2816","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5702_CR22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00520-012-1459-y","volume":"20","author":"AD Vandyk","year":"2012","unstructured":"Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey D (2012) Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer 20:1589\u20131599. https:\/\/doi.org\/10.1007\/s00520-012-1459-y","journal-title":"Support Care Cancer"},{"key":"5702_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","volume":"73","author":"I El Majzoub","year":"2019","unstructured":"El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM et al (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73:79\u201387. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.04.019","journal-title":"Ann Emerg Med"},{"key":"5702_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/1078155219836155","volume":"26","author":"B Rasor","year":"2019","unstructured":"Rasor B, Henderson R, Chan K (2019) Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital. J Oncol Pharm Pract 26:60\u201366. https:\/\/doi.org\/10.1177\/1078155219836155","journal-title":"J Oncol Pharm Pract"},{"key":"5702_CR25","unstructured":"Health UDo, Services H. Common Terminology Criteria for Adverse Events (CTCAE) v5. 0. Published Nov. 27, 2017. In. 2018"},{"key":"5702_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.12968\/hmed.2018.79.7.372","volume":"79","author":"BA Pickwell-Smith","year":"2018","unstructured":"Pickwell-Smith BA, So AC, Board RE (2018) Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med (Lond) 79:372\u2013377. https:\/\/doi.org\/10.12968\/hmed.2018.79.7.372","journal-title":"Br J Hosp Med (Lond)"},{"key":"5702_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/NCC.0000000000000360","volume":"40","author":"RS Lash","year":"2017","unstructured":"Lash RS, Bell JF, Reed SC, Poghosyan H, Rodgers J et al (2017) A systematic review of emergency department use among cancer patients. Cancer Nurs 40:135\u2013144. https:\/\/doi.org\/10.1097\/NCC.0000000000000360","journal-title":"Cancer Nurs"},{"key":"5702_CR28","doi-asserted-by":"publisher","first-page":"e190979","DOI":"10.1001\/jamanetworkopen.2019.0979","volume":"2","author":"JM Caterino","year":"2019","unstructured":"Caterino JM, Adler D, Durham DD, Yeung S-CJ, Hudson MF et al (2019) Analysis of diagnoses, symptoms, medications, and admissions among patients with cancer presenting to emergency departments. JAMA Netw Open 2:e190979. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0979","journal-title":"JAMA Netw Open"},{"key":"5702_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s12913-019-4509-z","volume":"19","author":"PH Dufton","year":"2019","unstructured":"Dufton PH, Drosdowsky A, Gerdtz MF, Krishnasamy M (2019) Socio-demographic and disease related characteristics associated with unplanned emergency department visits by cancer patients: a retrospective cohort study. BMC Health Serv Res 19:647. https:\/\/doi.org\/10.1186\/s12913-019-4509-z","journal-title":"BMC Health Serv Res"},{"key":"5702_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7314\/APJCP.2014.15.2.687","volume":"15","author":"O Tanriverdi","year":"2014","unstructured":"Tanriverdi O, Beydilli H, Yildirim B, Karagoz U (2014) Single center experience on causes of cancer patients visiting the emergency department in southwest Turkey. Asian Pac J Cancer Prev 15:687\u2013690","journal-title":"Asian Pac J Cancer Prev"},{"key":"5702_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J ImmunoTher Cancer 6:74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1","journal-title":"J ImmunoTher Cancer"},{"key":"5702_CR32","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM et al (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112:1904\u20131910. https:\/\/doi.org\/10.1038\/bjc.2015.180","journal-title":"Br J Cancer"},{"key":"5702_CR33","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ejca.2008.06.031","volume":"44","author":"LJAC Hawinkels","year":"2008","unstructured":"Hawinkels LJAC, Zuidwijk K, Verspaget HW, de Jonge-Muller ESM, Duijn WV et al (2008) VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44:1904\u20131913. https:\/\/doi.org\/10.1016\/j.ejca.2008.06.031","journal-title":"Eur J Cancer"},{"key":"5702_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13046-015-0256-0","volume":"34","author":"G He","year":"2015","unstructured":"He G, Zhang H, Zhou J, Wang B, Chen Y et al (2015) Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1\/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 34:141. https:\/\/doi.org\/10.1186\/s13046-015-0256-0","journal-title":"J Exp Clin Cancer Res"},{"key":"5702_CR35","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"MHJ van den Beuken-van Everdingen","year":"2007","unstructured":"van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437\u20131449. https:\/\/doi.org\/10.1093\/annonc\/mdm056","journal-title":"Ann Oncol"},{"key":"5702_CR36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jpainsymman.2006.08.003","volume":"32","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S et al (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32:532\u2013540. https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.08.003","journal-title":"J Pain Symptom Manag"},{"key":"5702_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1200\/jco.2015.33.29_suppl.188","volume":"33","author":"DM Zylla","year":"2015","unstructured":"Zylla DM, Richter S, Shapiro AC, Gupta P (2015) Impact of opioid use on survival in patients with newly diagnosed stage IV non-hematologic malignancies. J Clin Oncol 33:188. https:\/\/doi.org\/10.1200\/jco.2015.33.29_suppl.188","journal-title":"J Clin Oncol"},{"key":"5702_CR38","doi-asserted-by":"publisher","unstructured":"Jairam V, Yang DX, Yu JB, Park HS (2019) Emergency department visits for opioid overdoses among patients with cancer. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djz233","DOI":"10.1093\/jnci\/djz233"},{"key":"5702_CR39","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12913-018-3361-x","volume":"18","author":"MB S\u00f8vs\u00f8","year":"2018","unstructured":"S\u00f8vs\u00f8 MB, Hermansen SB, F\u00e6rk E, Lindskou TA, Ludwig M et al (2018) Diagnosis and mortality of emergency department patients in the North Denmark region. BMC Health Serv Res 18:548. https:\/\/doi.org\/10.1186\/s12913-018-3361-x","journal-title":"BMC Health Serv Res"},{"key":"5702_CR40","doi-asserted-by":"crossref","unstructured":"Moore E, Munoz-Arroyo R, Schofield L, Radley A, Clark D et al (2018) Death within 1 year among emergency medical admissions to Scottish hospitals: incident cohort study. BMJ Open:e021432","DOI":"10.1136\/bmjopen-2017-021432"},{"key":"5702_CR41","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/jco.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905\u20131912. https:\/\/doi.org\/10.1200\/jco.2017.77.0305","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05702-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05702-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05702-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:40:19Z","timestamp":1629934819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05702-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5702"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05702-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hacettepe University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}